美国及全球丙型肝炎病毒感染直接抗病毒治疗方案的可及现状
The Current Status of US and Global Access to Direct-Acting Antiviral Regimens for Hepatitis C Virus Infection.
作者信息
Graham Camilla S
机构信息
Division of Infectious Disease Beth Israel Deaconess Medical Center Boston MA.
出版信息
Clin Liver Dis (Hoboken). 2020 Jul 21;16(1):16-19. doi: 10.1002/cld.925. eCollection 2020 Jul.
Abstract
Watch an interview with the author.
摘要
观看对作者的采访。
相似文献
1
The Current Status of US and Global Access to Direct-Acting Antiviral Regimens for Hepatitis C Virus Infection.美国及全球丙型肝炎病毒感染直接抗病毒治疗方案的可及现状
Clin Liver Dis (Hoboken). 2020 Jul 21;16(1):16-19. doi: 10.1002/cld.925. eCollection 2020 Jul.
2
Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis.美国丙型肝炎病毒感染全口服直接抗病毒药物的初始吸收率、治疗时间和真实世界疗效：一项回顾性队列分析。
PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
3
Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.用于治疗慢性丙型肝炎感染的基于干扰素和不含干扰素的直接抗病毒方案的直接成本。
J Viral Hepat. 2016 Sep;23(9):677-86. doi: 10.1111/jvh.12532. Epub 2016 Mar 21.
4
Increased peripheral CD4 regulatory T cells persist after successful direct-acting antiviral treatment of chronic hepatitis C.慢性丙型肝炎经直接作用抗病毒治疗后外周血 CD4 调节性 T 细胞持续增加。
J Hepatol. 2017 May;66(5):888-896. doi: 10.1016/j.jhep.2016.12.019. Epub 2016 Dec 29.
5
Experience of a Portuguese Center: Effectiveness of Direct-Acting Antiviral Therapy for Hepatitis C.一家葡萄牙中心的经验：丙型肝炎直接抗病毒治疗的有效性
Acta Med Port. 2019 Mar 29;32(3):189-194. doi: 10.20344/amp.10655.
6
'Real-life' experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease.终末期肾病患者使用丙型肝炎病毒直接抗病毒药物的“真实世界”经验。
Int J Artif Organs. 2018 Jul;41(7):363-370. doi: 10.1177/0391398818763478. Epub 2018 Mar 27.
7
Immunosuppressive and antiviral treatment of hepatitis C virus-associated glomerular disease: A long-term follow-up.丙型肝炎病毒相关性肾小球疾病的免疫抑制和抗病毒治疗：长期随访
Int J Artif Organs. 2018 Jun;41(6):306-318. doi: 10.1177/0391398818762358. Epub 2018 Mar 29.
8
Male Sexual Dysfunction Among Egyptian Patients with Chronic Hepatitis C Virus Infection Before and After Direct-Acting Antiviral Drugs.埃及慢性丙型肝炎病毒感染患者直接抗病毒药物治疗前后的男性性功能障碍。
J Sex Med. 2019 Mar;16(3):402-409. doi: 10.1016/j.jsxm.2019.01.309.
9
Direct-acting antiviral therapy for hepatitis C virus infection in the kidney transplant recipient.直接作用抗病毒疗法治疗肾移植受者丙型肝炎病毒感染。
Kidney Int. 2018 Mar;93(3):560-567. doi: 10.1016/j.kint.2017.10.024. Epub 2018 Jan 9.
10
[Selection of direct-acting antiviral agents for chronic hepatitis C infection].[慢性丙型肝炎感染直接抗病毒药物的选择]
Zhonghua Gan Zang Bing Za Zhi. 2018 Mar 20;26(3):169-172. doi: 10.3760/cma.j.issn.1007-3418.2018.03.002.
引用本文的文献
1
Global disparities in access to hepatitis C medicines before and during the early phase of the COVID-19 pandemic: an ARIMA-based interrupted time series analysis.2019年冠状病毒病大流行早期之前及期间丙型肝炎药物获取情况的全球差异：基于自回归积分滑动平均模型的中断时间序列分析
BMJ Public Health. 2025 Jun 25;3(1):e001340. doi: 10.1136/bmjph-2024-001340. eCollection 2025.
2
Reduced injection risk behavior with co-located hepatitis C treatment at a syringe service program: The accessible care model.在美沙酮维持治疗点实施共置性丙型肝炎治疗可降低注射风险行为：可及性护理模式。
PLoS One. 2024 Aug 29;19(8):e0308102. doi: 10.1371/journal.pone.0308102. eCollection 2024.
3
Global burden of primary liver cancer and its association with underlying aetiologies, sociodemographic status, and sex differences from 1990-2019: A DALY-based analysis of the Global Burden of Disease 2019 study.全球原发性肝癌负担及其与潜在病因、社会人口地位和性别差异的关系：基于残疾调整生命年的 2019 年全球疾病负担研究分析。
Clin Mol Hepatol. 2023 Apr;29(2):433-452. doi: 10.3350/cmh.2022.0316. Epub 2023 Jan 4.
4
Circulating thrombospondin 2 levels reflect fibrosis severity and disease activity in HCV-infected patients.循环血栓反应蛋白 2 水平反映 HCV 感染患者的纤维化严重程度和疾病活动度。
Sci Rep. 2022 Nov 7;12(1):18900. doi: 10.1038/s41598-022-23357-9.
5
Randomized clinical trial: Direct-acting antivirals as treatment for hepatitis C in people who inject drugs: Delivered in needle and syringe programs via directly observed therapy versus fortnightly collection.随机临床试验：直接作用抗病毒药物治疗注射吸毒者丙型肝炎：通过直接观察治疗与每两周收集药物在针具交换项目中提供。
J Viral Hepat. 2022 Aug;29(8):646-653. doi: 10.1111/jvh.13701. Epub 2022 May 26.
6
Modeling-Based Response-Guided DAA Therapy for Chronic Hepatitis C to Identify Individuals for Shortening Treatment Duration.基于模型的应答引导直接抗病毒药物疗法治疗慢性丙型肝炎以确定可缩短治疗疗程的个体。
Open Forum Infect Dis. 2022 Mar 22;9(5):ofac157. doi: 10.1093/ofid/ofac157. eCollection 2022 May.
7
Hepatitis C coinfection and extrahepatic cancer incidence among people living with HIV.丙型肝炎合并感染与 HIV 感染者的肝外癌症发病情况。
HIV Med. 2022 Jul;23(6):620-628. doi: 10.1111/hiv.13218. Epub 2021 Dec 23.
8
Prevalence of Hepatitis B and Hepatitis C Infections among Incarcerated Individuals in Iran: A Cross-Sectional National Bio-behavioral Study in 2019.伊朗在押人员中乙型肝炎和丙型肝炎感染的患病率：2019年全国性横断面生物行为研究
Pathogens. 2021 Nov 21;10(11):1522. doi: 10.3390/pathogens10111522.
9
New hope for hepatitis C virus: Summary of global epidemiologic changes and novel innovations over 20 years.丙型肝炎病毒的新希望：20 多年来全球流行病学变化和新创新的总结。
World J Gastroenterol. 2021 Aug 7;27(29):4818-4830. doi: 10.3748/wjg.v27.i29.4818.
10
Global Epidemiology of Chronic Liver Disease.慢性肝病的全球流行病学
Clin Liver Dis (Hoboken). 2021 Jun 4;17(5):365-370. doi: 10.1002/cld.1061. eCollection 2021 May.
本文引用的文献
1
New virological tools for screening, diagnosis and monitoring of hepatitis B and C in resource-limited settings.用于资源有限环境下乙型和丙型肝炎的筛查、诊断和监测的新病毒学工具。
J Hepatol. 2018 Oct;69(4):916-926. doi: 10.1016/j.jhep.2018.05.017. Epub 2018 May 23.
2
Five Questions Concerning Managing Hepatitis C in the Justice System: Finding Practical Solutions for Hepatitis C Virus Elimination.五个关于司法系统中丙型肝炎管理的问题：为丙型肝炎病毒消除寻找切实可行的解决方案。
Infect Dis Clin North Am. 2018 Jun;32(2):323-345. doi: 10.1016/j.idc.2018.02.014.
3
Access to medicines and hepatitis C in Africa: can tiered pricing and voluntary licencing assure universal access, health equity and fairness?非洲的药品获取与丙型肝炎：分级定价和自愿许可能否确保普遍获取、健康公平与公正？
Global Health. 2017 Sep 13;13(1):73. doi: 10.1186/s12992-017-0297-6.
4
A path to eradication of hepatitis C in low- and middle-income countries.低收入和中等收入国家消除丙型肝炎的途径。
Antiviral Res. 2015 Jul;119:89-96. doi: 10.1016/j.antiviral.2015.01.004. Epub 2015 Jan 20.
5
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.在发展中国家用于大规模治疗获取项目的丙型肝炎直接抗病毒药物的最低生产成本。
Clin Infect Dis. 2014 Apr;58(7):928-36. doi: 10.1093/cid/ciu012. Epub 2014 Jan 6.
Zotero 插件